NSCLC

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

By

The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.

Expression Levels of SMARCA4/BRG1 Gene Indicates Response to Chemotherapy

By

Significant sensitivity to cisplatin-based chemotherapy is signaled by the presence of low expression of SMARCA4/BRG1 in patients with earlier-stage NSCLC. Low expression of SMARCA4/BRG1 was also linked to a poor prognosis.

Combination of Immune Checkpoint Blockers Shows Promise in Lung Cancer

By

Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.

Newly Approved NSCLC Diagnostic Assay Accurately Assesses for Treatment Options

By

An immunohistochemistry (IHC) test for rearrangements of the gene for anaplastic lymphoma kinase (ALK) receptor performed more accurately than another commonly used IHC assay, including reducing the rate of false positives.

Outcomes Are Comparable With Treatment Allocation Based on CGA or Performance Status and Age in Elderly Patients with NSCLC

Outcomes Are Comparable With Treatment Allocation Based on CGA or Performance Status and Age in Elderly Patients with NSCLC

By

Treatment allocation based on comprehensive geriatric assessment (CGA) did not improve treatment failure free survival or overall survival, but treatment toxicity was slightly reduced, in elderly patients with NSCLC.

NSCLC: Bevacizumab Beyond Disease Progression After First-line Bevacizumab

NSCLC: Bevacizumab Beyond Disease Progression After First-line Bevacizumab

By

Addition of bevacizumab to chemotherapy beyond disease progression may be effective in patients with advanced non-small cell lung cancer (NSCLC).

Younger Age Linked With Targetable Genotype in NSCLC

By

Younger age is associated with an increased likelihood of having a targetable genotype in patients with non-small cell lung cancer (NSCLC).

SBRT Well Tolerated in Patients With Early Stage and Centrally Located NSCLC

By

Treatment with stereotactic body radiotherapy (SBRT) was well-tolerated by patients whose non-small cell lung cancer (NSCLC) tumors were located centrally in the chest and who were not candidates for surgery.

Rare Mutation May Extend Survival in Lung Cancer Patients With Brain Metastases

Rare Mutation May Extend Survival in Lung Cancer Patients With Brain Metastases

By

Most patients with NSCLC that has metastasized to the brain have a dire prognosis. However, researchers have identified a subset of those patients who have a rare genetic mutation and are living significantly longer than patients without the mutation.

Intensity-Modulated Radiation Lessens Side Effects for Lung Cancer Patients

Intensity-Modulated Radiation Lessens Side Effects for Lung Cancer Patients

By

An analysis of an international, cooperative-led trial of patients with locally advanced NSCLC has shown that those who received IMRT had less severe lung toxicity and were able to better tolerate their chemotherapy, compared with patients who received 3-D CRT.

Clinical Trial Demonstrates Superior Results With Immunotherapy vs Chemotherapy for Lung Cancer

By

An international team of cancer researchers announced game-changing results in the treatment of certain lung cancers with nivolumab compared with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.

Novel diagnostic tool for ethnically diverse patients with non-small cell lung cancer

Novel diagnostic tool for ethnically diverse patients with non-small cell lung cancer

By

A panel of five serum microRNAs has been identified as a potential biomarker to diagnose early stage non-small cell lung cancer.

Multimodality treatment for metastatic lung cancer with surgery may improve survival

By

Patients with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection of all or part of the lung if combined with chemotherapy and radiation therapy.

Immunotherapy drug improves survival for common form of lung cancer

By

Individuals with squamous non-small cell lung cancer (NSCLC) fared better when receiving nivolumab when compared to those receiving more standard chemotherapy, according to a recent clinical trial.

Stereotactic ablative radiotherapy (SABR) offers better overall survival than surgery in early lung cancer

Stereotactic ablative radiotherapy (SABR) offers better overall survival than surgery in early lung cancer

By

Patients with operable stage I non-small cell lung cancer can achieve better overall survival rates if treated with stereotactic ablative radiotherapy (SABR) opposed to the current standard therapy.

Phase I trial of lung cancer drug identifies multiple types of drug resistance

By

Researchers urge for new targeted inhibitors and combinations to combat tumors' constant and varied molecular adaptation.

Liquid biopsy: A new tool in the management of NSCLC

Liquid biopsy: A new tool in the management of NSCLC

By

This developing technology allows serial monitoring to better gauge response to treatment and prognosis for patients with non-small cell lung cancer.

Mutation that drives NSCLC also found in one-quarter of small cell lung cancers

By

Research indicates that a known mutation in non-small cell lung cancer (NSCLC) is also present in small cell lung cancer, implying that some effective treatments for NSCLC can also be used on the more aggressive form of the disease.

Stereotactic body radiation therapy (SBRT) plus chemotherapy improves survival among patients with stage 4 lung cancer

By

Combining stereotactic body radiation therapy (SBRT) with a specific chemotherapy regimen more than doubled survival rates for certain patients with stage 4 lung cancer, according to recent research data.

Treatment-resistant non-small cell lung cancer (NSCLC) responds to new drug

By

An oral drug called ASP8273 caused tumor shrinkage in patients in a phase I clinical trial, according to research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

Postoperative radiation therapy improves overall survival in resected NSCLC

By

Patients with non-small lung cancer (NSCLC) that received postoperative radiation therapy (PORT) lived an average of 4 months longer, when compared with patients who had the same disease progression and treatment criteria.

Crizotinib treatment effective against ROS1-positive lung cancer

By

Treatment with the drug crizotinib has been effective for stopping lung tumor growth driven by rearrangements of the ROS1 gene.

EGFR mutations in circulating tumor DNA (ctDNA) can be used in place of tumor tissue in non-small cell lung cancer (NSCLC) diagnostics

By

Epidermal growth factor receptor mutations found in ctDNA in the plasma of patients with advanced non-small cell lung cancer correlates well with the EGFR mutations from patient-matched tumor tissue DNA.

Managing adverse effects of NSCLC treatment

Managing adverse effects of NSCLC treatment

EGFR inhibitors are widely used to treat metastatic NSCLC; however, they can cause various adverse effects that differ from those caused by traditional intravenous chemotherapy.

Overall survival in advanced NSCLC increased with less toxic chemotherapy

By

A 10-year study shows that increased availability of better systemic chemotherapies and targeted therapies for patients with advanced non-small cell lung cancer coincides with increased usage of these therapies.

Noninvasive advanced image analysis may improve care for lung cancer patients

By

Lung cancer patients could receive more precise treatment, and their progress could be better tracked by using a new high-tech method of non-invasive medical imaging analysis, according to a new study.

Experts weigh in on managing elderly patients with NSCLC

By

Approximately half of all patients with a diagnosis of non-small cell lung cancer are age 70 years or older, yet elderly patients are not well represented in clinical trials.

PD-L1 protein levels predict response to immunotherapy in lung cancer patients

By

Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.

PET imaging before surgery reduces unnecessary lung surgery by half

By

New quantitative data suggests that 30% of the surgeries performed for non-small cell lung cancer patients in a community-wide clinical study were deemed unnecessary.

Immunotherapy data marks new era for treating lung cancer

Immunotherapy data marks new era for treating lung cancer

By

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs